Meditope Biosciences Inc is categorized under Commercial Biotechnical Research in Pasadena, CA and active since 2012.
Meditope Biosciences Inc was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Stephanie Hsieh at the company’s single location by writing to 301 North Lake Avenue # 900, Pasadena, California CA 91101 or by phoning (626) 278-2478. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Meditope Biosciences Inc |
Contact Person: | Stephanie Hsieh |
Address: | 301 North Lake Avenue # 900, Pasadena, California 91101 |
Phone Number: | (626) 278-2478 |
Annual Revenue (USD): | $50.000 to $99.999 |
Founded: | 2012 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Commercial Biotechnical Research |
SIC Code: | 8731 |
NAICS Code: | 541711 |
Share This Business: |
Meditope Biosciences Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Stephanie Hsieh for inquiries that concern Meditope Biosciences Inc by calling the company number (626) 278-2478, as your correspondence is most welcome. Additionally, the physical location of the single location of Meditope Biosciences Inc can be found at the coordinates 34.151007,-118.13254 as well as the street address 301 North Lake Avenue # 900 in Pasadena, California 91101.
For its online presence, you may visit Meditope Biosciences Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.